~~<i id='76CDF691D2'><strike id='76CDF691D2'><tt id='76CDF691D2'><pre id='76CDF691D2'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：Wikipedia 2025-09-27 15:07:30 Page View：6142

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

knowledge

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Think you might have Covid

AdobeIfyouhaveacough,fever,orshortnessofbreath,howcanyoutellifyou’vegotCovid-19,acommoncold,theordin

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Research misconduct: Proposed new rules face resistance

AdobeResearchuniversitiesarevoicingconcernsoversomeproposedchangestotheprocessforreviewingscientific